There were no safety concerns identified among older adults following revaccination with the investigational respiratory syncytial virus vaccine mRNA-1345, and immune responses elicited by ...

Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK ...

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...

Northwestern University sued vaccine maker Moderna, Inc. on Wednesday, October 16, in the U.S. District Court for the ...

此外，近日GSK公布其RSV疫苗在预防60岁以上老年人3年（3个完整流行季）的保护效力，累积保护效力为63%，然而却呈现显著的下降趋势——从第1年的83%到第2年的56%再到第3年的48%，而Arexvy的初始效力在三款疫苗中已是佼佼者。

点击上方“Vaccine前研”，关注最新疫苗动态自21世纪伊始，呼吸道病毒乃全球致死率之主要因素，相关疫情屡屡发生，尤以近期之SARS-CoV-2大流行最为显著，其后果之严重令人扼腕。此外，呼吸道合胞病毒（RSV）与流感病毒等，亦持续侵袭个体之呼吸道 ...

GSK filed two lawsuits at the US District of Delaware on 15 October saying that Moderna’s mRNA vaccine product Spikevax ...

Moderna Inc.’s shots for Covid-19 and respiratory syncytial virus infringe as many as seven GSK Plc patents related to mRNA ...

A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent ...

London: British drugmaker GlaxoSmithKline (GSK) sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its ...

GlaxoSmithKline has filed lawsuits against Moderna in a Delaware federal court, alleging infringement of patents related to ...